IGC PHARMA INC (IGC) Stock News

12 Health Care Stocks Moving In Thursday's After-Market Session

Mentions: XTNT VNRX AZTR SNTI ...

IGC Pharma Welcomes Strategic Investment from Advisors

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Expedia Group, Inc. (EXPE): Among the Best Cruise Stocks to Buy According to Hedge Funds

We recently published a list of 12 Best Cruise Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Expedia Group, Inc. (NASDAQ:EXPE) stands against other best cruise stocks to buy according to hedge funds. Overview of the Cruise Line Industry The cruise industry is on […]

Mentions: EXPE JPM HAS CALM ...

Hasbro, Inc. (HAS): A Bull Case Theory

We came across a bullish thesis on Hasbro, Inc. (HAS) on Substack by The Reservist. In this article, we will summarize the bulls’ thesis on HAS. Hasbro, Inc. (HAS)’s share was trading at $50.71 as of April 8th. HAS’s trailing and forward P/E were 18.44 and 11.99 respectively according to Yahoo Finance. Hasbro represents a compelling investment […]

Mentions: HAS VZ DIS EXPE ...

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25"

IGC Pharma Reports Third Quarter Fiscal 2025 Results

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results”

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Advances IGC-AD1 Research to Potentially Deliver ‘Breakthrough Treatment’ in Alzheimer’s Disease

Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual Meeting

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Preclinical Research Evaluating New Molecule IGC-1C in Treatment of Alzheimer’s Disease

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

InvestorNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) AI-Driven Approach Reveals ‘Promising Opportunity’ for IGC-1A to Be a Potential GLP-1 Agonist

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

IGC Announces Results of its 2024 Annual Stockholders Meeting

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease